ACRS insider transaction filings
Aclaris Therapeutics, Inc. — 46 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-04. Screen ACRS transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-04 | 4 | Kolbeck Roland Wilhelm — Chief Scientific Officer | Option exercise (M): 36,375 · Tax withholding (F): 12,385 @ $5.20 · Option exercise (M): 36,375 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Humphries William D. — Director | Option exercise (M): 11,580 · Grant/award (A): 42,350 (derivative) @ $0 · Grant/award (A): 10,987 (derivative) @ $0 · Option exercise (M): 11,580 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Molineaux Christopher P. — Director | Option exercise (M): 11,580 · Grant/award (A): 42,350 (derivative) @ $0 · Grant/award (A): 10,987 (derivative) @ $0 · Option exercise (M): 11,580 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Mehra Anand — Director | Option exercise (M): 11,580 · Grant/award (A): 42,350 (derivative) @ $0 · Grant/award (A): 10,987 (derivative) @ $0 · Option exercise (M): 11,580 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | GOWEN MAXINE — Director | Option exercise (M): 11,580 · Grant/award (A): 42,350 (derivative) @ $0 · Grant/award (A): 10,987 (derivative) @ $0 · Option exercise (M): 11,580 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | MILANO VINCENT — Director | Option exercise (M): 11,580 · Grant/award (A): 42,350 (derivative) @ $0 · Grant/award (A): 10,987 (derivative) @ $0 · Option exercise (M): 11,580 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | SCHIFF ANDREW N — Director | Option exercise (M): 11,580 · Grant/award (A): 42,350 (derivative) @ $0 · Grant/award (A): 10,987 (derivative) @ $0 · Option exercise (M): 11,580 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | Hall Jesse Wayne — Chief Medical Officer | Option exercise (M): 36,375 · Tax withholding (F): 9,330 @ $4.41 · Option exercise (M): 36,375 (derivative) @ $0 | EDGAR |
| 2026-04-27 | 4 | Leonard Braden Michael — 10% owner | Sale (S): 300,000 @ $4.53 | EDGAR |
| 2026-03-03 | 4 | Balthaser Kevin — Chief Financial Officer | Option exercise (M): 2,375 · Tax withholding (F): 677 @ $2.87 · Option exercise (M): 2,375 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Kolbeck Roland Wilhelm — Chief Scientific Officer | Grant/award (A): 95,700 (derivative) @ $0 · Grant/award (A): 334,900 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Hall Jesse Wayne — Chief Medical Officer | Grant/award (A): 98,100 (derivative) @ $0 · Grant/award (A): 343,300 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Davis Hugh M. — President and COO, Director | Grant/award (A): 96,100 (derivative) @ $0 · Grant/award (A): 336,300 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Balthaser Kevin — Chief Financial Officer | Grant/award (A): 99,100 (derivative) @ $0 · Grant/award (A): 346,800 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Loerop James — Chief Business Officer | Grant/award (A): 97,700 (derivative) @ $0 · Grant/award (A): 341,900 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Walker Neal — CEO, Director | Grant/award (A): 274,800 (derivative) @ $0 · Grant/award (A): 961,700 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | Davis Hugh M. — President and COO, Director | Option exercise (M): 18,675 · Option exercise (M): 18,675 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | Balthaser Kevin — Chief Financial Officer | Option exercise (M): 22,025 · Tax withholding (F): 6,449 @ $3.47 · Option exercise (M): 22,025 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | Loerop James — Chief Business Officer | Option exercise (M): 20,875 · Tax withholding (F): 5,937 @ $3.47 · Option exercise (M): 20,875 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4 | Walker Neal — CEO, Director | Option exercise (M): 63,475 · Tax withholding (F): 18,611 @ $3.47 · Option exercise (M): 63,475 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4/A | Loerop James — Chief Business Officer | Option exercise (M): 11,250 · Option exercise (M): 7,500 · Option exercise (M): 14,750 · Tax withholding (F): 10,686 @ $3.51 · Option exercise (M): 11,250 (derivative) @ $0 · Option exercise (M): 7,500 (derivative) @ $0 · +1 more | EDGAR |
| 2026-02-03 | 4 | Balthaser Kevin — Chief Financial Officer | Option exercise (M): 14,750 · Tax withholding (F): 4,984 @ $3.51 · Option exercise (M): 14,750 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Loerop James — Chief Business Officer | Tax withholding (F): 15,980 @ $2.48 | EDGAR |
| 2026-02-03 | 4/A | Loerop James — Chief Business Officer | Tax withholding (F): 15,980 @ $2.48 | EDGAR |
| 2026-01-05 | 4 | Balthaser Kevin — Chief Financial Officer | Option exercise (M): 73,750 · Tax withholding (F): 19,934 @ $3.01 · Option exercise (M): 7,500 · Tax withholding (F): 2,250 @ $3.01 · Option exercise (M): 13,200 · Tax withholding (F): 4,461 @ $2.88 · +3 more | EDGAR |
| 2026-01-05 | 4 | Loerop James — Chief Business Officer | Option exercise (M): 73,750 · Tax withholding (F): 33,994 @ $3.01 · Option exercise (M): 18,150 · Tax withholding (F): 6,171 @ $2.88 · Option exercise (M): 73,750 (derivative) @ $0 · Option exercise (M): 18,150 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Walker Neal — CEO, Director | Option exercise (M): 29,150 · Tax withholding (F): 9,952 @ $2.88 · Option exercise (M): 29,150 (derivative) @ $0 | EDGAR |
| 2025-12-04 | 4 | Davis Hugh M. — President and COO, Director | Option exercise (M): 26,750 · Option exercise (M): 26,750 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | Kolbeck Roland Wilhelm — Chief Scientific Officer | Grant/award (A): 145,500 (derivative) @ $0 · Grant/award (A): 510,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Mehra Anand — Director | Option exercise (M): 4,793 · Grant/award (A): 42,350 (derivative) @ $0 · Grant/award (A): 11,580 (derivative) @ $0 · Option exercise (M): 4,793 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Humphries William D. — Director | Option exercise (M): 4,793 · Grant/award (A): 42,350 (derivative) @ $0 · Grant/award (A): 11,580 (derivative) @ $0 · Option exercise (M): 4,793 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Molineaux Christopher P. — Director | Option exercise (M): 4,793 · Grant/award (A): 42,350 (derivative) @ $0 · Grant/award (A): 11,580 (derivative) @ $0 · Option exercise (M): 4,793 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | GOWEN MAXINE — Director | Option exercise (M): 4,793 · Grant/award (A): 42,350 (derivative) @ $0 · Grant/award (A): 11,580 (derivative) @ $0 · Option exercise (M): 4,793 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | MILANO VINCENT — Director | Option exercise (M): 4,793 · Grant/award (A): 42,350 (derivative) @ $0 · Grant/award (A): 11,580 (derivative) @ $0 · Option exercise (M): 4,793 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | SCHIFF ANDREW N — Director | Option exercise (M): 4,793 · Grant/award (A): 42,350 (derivative) @ $0 · Grant/award (A): 11,580 (derivative) @ $0 · Option exercise (M): 4,793 (derivative) @ $0 | EDGAR |
| 2025-05-05 | 4 | Hall Jesse Wayne — Chief Medical Officer | Grant/award (A): 145,500 (derivative) @ $0 · Grant/award (A): 510,000 (derivative) @ $0 | EDGAR |
| 2025-05-05 | 4 | Walker Neal — CEO, Director | Option exercise (M): 9,467 · Tax withholding (F): 2,975 @ $1.38 · Option exercise (M): 9,467 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Walker Neal — CEO, Director | Option exercise (M): 9,467 · Tax withholding (F): 3,042 @ $1.48 · Option exercise (M): 9,467 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Walker Neal — CEO, Director | Option exercise (M): 9,466 · Tax withholding (F): 3,277 @ $1.99 · Option exercise (M): 9,466 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Monahan Joseph — Chief Scientific Officer | Option exercise (M): 50,000 · Option exercise (M): 10,925 · Tax withholding (F): 27,258 @ $1.99 · Option exercise (M): 50,000 (derivative) @ $0 · Option exercise (M): 10,925 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Balthaser Kevin — Chief Financial Officer | Option exercise (M): 1,100 · Option exercise (M): 2,375 · Tax withholding (F): 727 @ $1.99 · Option exercise (M): 1,100 (derivative) @ $0 · Option exercise (M): 2,375 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Davis Hugh M. — President and COO, Director | Grant/award (A): 74,700 (derivative) @ $0 · Grant/award (A): 261,600 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Walker Neal — INTERIM CEO, Director | Option exercise (M): 9,467 · Tax withholding (F): 3,559 @ $2.48 · Option exercise (M): 9,467 (derivative) @ $0 · Grant/award (A): 253,900 (derivative) @ $0 · Grant/award (A): 888,800 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Monahan Joseph — Chief Scientific Officer | Option exercise (M): 7,500 · Option exercise (M): 14,750 · Tax withholding (F): 11,317 @ $2.48 · Option exercise (M): 7,500 (derivative) @ $0 · Option exercise (M): 14,750 (derivative) @ $0 · Grant/award (A): 83,900 (derivative) @ $0 · +1 more | EDGAR |
| 2025-02-04 | 4 | Balthaser Kevin — Chief Financial Officer | Option exercise (M): 14,750 · Tax withholding (F): 5,816 @ $2.48 · Option exercise (M): 14,750 (derivative) @ $0 · Grant/award (A): 88,100 (derivative) @ $0 · Grant/award (A): 308,200 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Loerop James — Chief Business Officer | Option exercise (M): 11,250 · Option exercise (M): 7,500 · Option exercise (M): 14,750 · Tax withholding (F): 15,447 @ $2.48 · Option exercise (M): 11,250 (derivative) @ $0 · Option exercise (M): 7,500 (derivative) @ $0 · +3 more | EDGAR |
Recent 8-K events — Aclaris Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-28 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-11 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-03-10 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-02-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-06 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ACRS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →